Volume 44, Issue 2, Pages (February 2006)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 61, Issue 1, Pages (July 2014)
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
Volume 59, Issue 1, Pages (July 2013)
Inflammasomes in liver diseases
Volume 50, Issue 4, Pages (April 2009)
MELD: the holy grail of organ allocation?
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis  Wichit Srikureja,
Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic.
Reply to: “Serum HBV pgRNA as a clinical marker for cccDNA activity”
Effects of antiepileptic drug on thyroid hormones in patients with epilepsy: A meta- analysis  Yin-Xi Zhang, Chun-Hong Shen, Qi-Lun Lai, Gao-Li Fang, Wen-Jie.
Extramedullary Relapse of Acute Leukemia after Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment, and Clinical.
Volume 68, Issue 5, Pages (May 2018)
New directions for cell-based therapies in acute liver failure
Volume 51, Issue 6, Pages (December 2009)
Reactive oxygen species in the normal and acutely injured liver
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
NS5A inhibitors in the treatment of hepatitis C
Volume 53, Issue 2, Pages (February 2008)
The Myocardial Protective Effects of a Moderate-Potassium Blood Cardioplegia in Pediatric Cardiac Surgery: A Randomized Controlled Trial  Yang Liu, MD,
Milder phenotype with SCN1A truncation mutation other than SMEI
Value of radiotherapy after radical surgery for esophageal carcinoma: a report of 495 patients  Ze Fen Xiao, MD, Zong Yi Yang, MD, Jun Liang, MD, Yan.
Volume 44, Issue 6, Pages (June 2006)
Immigration and viral hepatitis
Volume 66, Issue 1, Pages 1-4 (January 2017)
Ype P. de Jong, Charles M. Rice, Alexander Ploss  Journal of Hepatology 
Prevalence and treatment gap of active convulsive epilepsy: A large community-based survey in rural West China  Jia Hu, Yang Si, Dong Zhou, Jie Mu, Juan.
Living donor liver transplantation: is the hype over?
Nicolas Moniaux, Jamila Faivre  Journal of Hepatology 
The place of downstaging for hepatocellular carcinoma
Volume 68, Issue 3, Pages (March 2018)
Volume 65, Issue 4, Pages (October 2016)
Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic.
Hepatitis C core protein – The “core” of immune deception?
Targeting gut flora to prevent progression of hepatocellular carcinoma
Amalia Gastaldelli, Giulio Marchesini  Journal of Hepatology 
Treatment of Acute Leukemia with Unmanipulated HLA-Mismatched/Haploidentical Blood and Bone Marrow Transplantation  Xiao-Jun Huang, Dai-Hong Liu, Kai-Yan.
Haploidentical Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic.
Impact of Pretransplantation Risk Factors on Post Transplantation Outcome of Patients with Acute Myeloid Leukemia in Remission after Haploidentical Hematopoietic.
Volume 62, Issue 3, Pages (March 2015)
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
The results of stent graft versus medication therapy for chronic type B dissection  Xin Jia, MD, Wei Guo, MD, Tian-xiao Li, MD, Sheng Guan, MD, Rui-min.
Volume 65, Issue 2, Pages (August 2016)
Volume 57, Issue 5, Pages (November 2012)
Volume 50, Issue 4, Pages (April 2009)
Positive Results of Serum Galactomannan Assays and Pulmonary Computed Tomography Predict the Higher Response Rate of Empirical Antifungal Therapy in.
Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong
Immigration and viral hepatitis
The potential of induced pluripotent stem cell derived hepatocytes
Volume 44, Issue 5, Pages (May 2006)
The impact of intestinal microflora on serum bilirubin levels
Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia  Yu Wang,
Volume 63, Issue 1, Pages (July 2015)
Familial amyloidosis: Great progress for an orphan disease
Volume 66, Issue 1, Pages (January 2017)
The use of hemospray in portal hypertensive bleeding; a case series
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
Volume 66, Issue 4, Pages (April 2017)
New trials and results in systemic treatment of HCC
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Chimeric mouse model of hepatitis B virus infection
Volume 42, Issue 4, Pages (April 2005)
Mirjam B. Zeisel, Marine Turek, Thomas F. Baumert 
MELD: the holy grail of organ allocation?
Volume 65, Issue 4, Pages (October 2016)
Presentation transcript:

Volume 44, Issue 2, Pages 317-324 (February 2006) Evaluation of a bioartificial liver based on a nonwoven fabric bioreactor with porcine hepatocytes in pigs  Lan Juan Li, Wei Bo Du, Yi Min Zhang, Jun Li, Xiao Ping Pan, Jia Jia Chen, Hong Cui Cao, Yu Chen, Yue Mei Chen  Journal of Hepatology  Volume 44, Issue 2, Pages 317-324 (February 2006) DOI: 10.1016/j.jhep.2005.08.006 Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 1 The schematic drawing depicts the configuration of the BAL treatment. Journal of Hepatology 2006 44, 317-324DOI: (10.1016/j.jhep.2005.08.006) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 2 The schematic drawing depicts the configuration of the NWF bioreactor. The bioreactor consists of a spirally wound, nonwoven polyester polytetrafluorethylene matrix (B) and 500 polysulfone-based hollow-fibers (C) in a plastic cartridge (A). Hepatocytes inoculate into the bioreactor via the side ports (D,E). The three-dimensional nonwoven fabric provides matrix for high density hepatocytes attachment and culture as small aggregates. Whole blood is perfused through the intralumen of hollow fibers via the side ports (F,G) for adequate oxygen supply and CO2 removal during the in vivo application. In addition, the semipermeable membrane of hollow fibers acts as exchangers and immuno-protective barriers, thereby preventing the hepatocytes from immuno-injury. The bioreactor has no oxygenation capillaries, therefore, oxygenated medium has to be used when operating the device in vitro. Journal of Hepatology 2006 44, 317-324DOI: (10.1016/j.jhep.2005.08.006) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Survival curves for the D-galactosamine induced FHF pigs in the BAL, the sham BAL and the FHF groups. Kaplan–Meier log-rank test: P<0.05, the BAL group versus the sham BAL and the FHF group. Journal of Hepatology 2006 44, 317-324DOI: (10.1016/j.jhep.2005.08.006) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Changes of parameters related liver functions in D-galactosamine induced FHF pigs during the BAL treatment. (a) Plasma ammonia levels in all groups. (Note. *P=0.01 versus both control groups by one-way ANOVA/t-test). (b) Serum glucose levels in all groups. (Note. *P<0.05 versus both control groups by one-way ANOVA/t-test). (c) Serum lactate levels in all groups. (Note. *P<0.01 versus both control by one-way ANOVA/t-test). (d) Prothrombin time changes in all groups. (Note. *P<0.05 versus the sham BAL groups by t-test). Journal of Hepatology 2006 44, 317-324DOI: (10.1016/j.jhep.2005.08.006) Copyright © 2005 European Association for the Study of the Liver Terms and Conditions